Showing 1761-1770 of 6370 results for "".
Maximize the marketing benefits of new dermatology devices
https://practicaldermatology.com/topics/practice-management/maximize-the-marketing-benefits-of-new-dermatology-devices/18354/New equipment and devices can mean new patients pouring through the doors of your dermatology office – but only if you market them effectively. Check out this Ekwa Marketing educational video to find out the best way to spread the word, and what marketing pitfalls to avoid.The Importance of Link Building_Part2
https://practicaldermatology.com/topics/practice-management/the-importance-of-link-building-part2/18544/Why is link-building important and how do you do it right? In the second of a 2-part series, Susan Hudson and Jamie Edson discuss ways to build natural and beneficial links. This video is part of a comprehensive suite of Ekwa.com Marketing Educational videos.AK Pearls: Managing Treatment Reactions
https://practicaldermatology.com/topics/skin-cancer-photoprotection/ak-pearls-managing-treatment-reactions/18741/Dr. Bhatia shares pearls for managing side effects and reactions to actinic keratosis treatment drugs. There are many adjunctive therapies to counter these reactions from emollients to barrier repair cream to time and some TLC for patients.Neurotoxin Tips and Trends
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/neurotoxin-tips-and-trends/18743/The latest trends in aesthetic dermatology call for a more natural look. Dr. Rossi says dermatologists are injecting less units of neurotoxins, more strategically placed for a more cosmetically pleasing look. He stresses the need to think about neuromodulation rather than paralyzing the muscles to aDrug Prices Soar, Amgen Files BLA for Biosimilar to Humira
https://practicaldermatology.com/topics/practice-management/dermwiretv-drug-prices-soar-amgen-files-bla-for-biosimilar-to-humira/18672/In this edition, Amgen Submits ABP 501—first Adalimumab biosimilar; prices for dermatology drugs jump and a survey explores patient knowledge of antibiotic resistance. Also, Almirall acquires Veltin from Sitefel/GSK.VShape Facial Contouring by Alma Lasers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/vshape-facial-contouring-by-alma-lasers/19251/VShape is a non-invasive and pain-free treatment for facial contouring. Performed throughout the world using Alma Lasers Accent Ultra medical aesthetic technology. vShape: Bipolar RF Technology“No-touch” Surgical Excision & “Double-freeze-thaw” Cryotherapy Techniques
https://practicaldermatology.com/topics/skin-cancer-photoprotection/conjunctival-scc/19861/A 68-year-old white male with a history of basal cell carcinoma of the right lower eyelid, surgically excised 10 years prior to presentation, was referred to the Ocular Oncology Service at Wills Eye Hospital, Philadelphia for an asymptomatic conjunctival lesion on the right eye. The patient was treaFDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/series/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.Is this the Golden Age of Hair Loss Treatment?
https://practicaldermatology.com/topics/hair-nails/is-this-the-golden-age-of-hair-loss-treatment/24036/A perfect storm of many new, unrelated scientific developments also has the potential to fundamentally reshape the way we think about a disease or disease group. Dr. Peter C. Friedman believes many recent breakthroughs have profoundly changed how general dermatologists can manage patients with hairRoflumilast Cream, 0.15%, for Atopic Dermatitis
https://practicaldermatology.com/issues/december-2024/Roflumilast-Cream-Atopic-Dermatitis/32840/Atopic dermatitis (AD) is a chronic, persistent inflammatory condition that significantly disrupts the quality of life of patients diagnosed with it. Moreover, AD presents challenges for clinicians when counseling patients on the management of their condition. Application frequency, treatment formul